EP0491415B1 — Low estrogen oral contraceptives
Assigned to Akzo Nobel NV · Expires 1996-04-03 · 30y expired
What this patent protects
Disclosed is a contraceptive regimen, and method of using the regimen, comprising 24 daily sequential dosage units of: a first phase comprising about 7 to 9 separate first dosage units containing a progestogen at a daily dosage equivalent in progestogenic activity to 100 mu g de…
USPTO Abstract
Disclosed is a contraceptive regimen, and method of using the regimen, comprising 24 daily sequential dosage units of: a first phase comprising about 7 to 9 separate first dosage units containing a progestogen at a daily dosage equivalent in progestogenic activity to 100 mu g desogestrel and an estrogen at a daily dosage equivalent in estrogenic activity to 25 mu g ethinyl estradiol ("EE"). A second phase of 7 to 9 second dosage units, each of the second dosage units containing a progestogen equivalent to 125 mu g desogestrel and an estrogen equivalent to 20 mu g EE. A third phase of 7 to 9 third dosage units, each unit containing a progestogen equivalent to 150 mu g desogestrel and an estrogen equivalent to 20 mu g EE. The kit generally has 28 daily dosage units wherein four of the daily dosage units contain no contraceptive steroid, or, alternatively, have only 24 dosage units with a four day "pill-free" period. The fourth phase may also be four dosage units containing a progestogen equivalent to 25 - 35 mu g desogestrel.
Drugs covered by this patent
- Natazia (DIENOGEST) · Mochida Pharmaceutical Co., Ltd.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.